D-0131-2020 Class III Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0131-2020 was initiated by Teva Pharmaceuticals USA on Sep 6, 2019 and is designated Class III. Reason for recall: GMP Deviation: lot not intended for commercial distribution. The recall status is terminated (terminated May 19, 2020). Affected quantity: 5,849 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 16, 2019
Initiation Date
Sep 6, 2019
Termination Date
May 19, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,849 bottles

Product description

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30 count bottle, Rx only, Manufactured by: Actabis Laboratories FL, Inc., Fort Lauderdale, FL, Distributed by: Actavis Pharma, Inc., Parsippany, NJ NDC 52544-692-30

Reason for recall

GMP Deviation: lot not intended for commercial distribution.

Distribution pattern

Product was distributed to 42 wholesalers and 11 retailers who may have further distribute the product throughout the United States, including Hawaii and Puerto Rico.

Code information

Lot # 1344864A, exp. date 10/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0131-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0131-2020. Report a data issue: hello@regdatalab.com.